In low-grade gliomas, adults have many mutations in genes such as IDH1 and TP53, but almost never in BRAF, while in pediatric tumors, about 85% have one of the two most commonly found abnormalities in BRAF (BRAF V600E mutation and BRAF-KIAA 1549 fusion) and are potential candidates for treatments with drugs inhibiting this pathway. The gene discussed is BRAF; the disease is glioma.